Michael James Leach, Emily Griffin, Sinead Hickmott, Holly Atkinson, Louise Bettiol, Eli Ristevski
{"title":"澳大利亚口服抗癌药物 10 年来的配药趋势。","authors":"Michael James Leach, Emily Griffin, Sinead Hickmott, Holly Atkinson, Louise Bettiol, Eli Ristevski","doi":"10.1002/pds.70126","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Oral anti-cancer medications (OAMs) are easily administered yet high-risk treatments. Few studies have investigated national and subnational trends in OAM dispensing. We aimed to examine 10-year trends in Australia's OAM dispensing at the national level as well as by state/territory and medication type/class.</p><p><strong>Methods: </strong>Aggregate data on Australia's OAM dispensing and population for 2014-2023 were sourced from Services Australia and the Australian Bureau of Statistics, respectively. Annual OAM dispensing rates (counts per 100 000 population) were calculated overall as well as by state/territory and medication type/class. Percentage change (Δ) in dispensing rates from 2014 to 2023 was determined. Where valid, Mann-Kendall trend tests were performed.</p><p><strong>Results: </strong>Australia-wide from 2014 to 2023, dispensing counts per 100 000 population for any OAMs increased nonlinearly from 3 475 to 3 930 (+Δ13%), hormonal OAMs decreased nonlinearly from 2 659 to 2 225 (-Δ16%), and non-hormonal OAMs exhibited a significant (p < 0.05) near-linear upward trend from 816 to 1 705 (+Δ109%). This coincided with a significant upward trend in the number of unique non-hormonal OAMs dispensed Australia-wide (+Δ187%). Percentage changes in non-hormonal OAM dispensing rates were greatest for protein kinase inhibitor (PKI) dispensing Australia-wide (+Δ232%), with a significant, near-linear upward trend from 286 to 950, and non-hormonal OAM dispensing in South Australia (+Δ141%), with a significant, near-linear upward trend from 820 to 1972.</p><p><strong>Conclusions: </strong>Australia's non-hormonal OAM dispensing increased over 2014-2023, mostly for PKIs. This likely reflects rising availability of and prescriber/patient demand for these medications, suggesting scope to pilot and expand OAM adherence and safety initiatives.</p>","PeriodicalId":19782,"journal":{"name":"Pharmacoepidemiology and Drug Safety","volume":"34 4","pages":"e70126"},"PeriodicalIF":2.4000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11934842/pdf/","citationCount":"0","resultStr":"{\"title\":\"Trends in the Dispensing of Oral Anti-Cancer Medications Across Australia Over 10 Years.\",\"authors\":\"Michael James Leach, Emily Griffin, Sinead Hickmott, Holly Atkinson, Louise Bettiol, Eli Ristevski\",\"doi\":\"10.1002/pds.70126\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Oral anti-cancer medications (OAMs) are easily administered yet high-risk treatments. Few studies have investigated national and subnational trends in OAM dispensing. We aimed to examine 10-year trends in Australia's OAM dispensing at the national level as well as by state/territory and medication type/class.</p><p><strong>Methods: </strong>Aggregate data on Australia's OAM dispensing and population for 2014-2023 were sourced from Services Australia and the Australian Bureau of Statistics, respectively. Annual OAM dispensing rates (counts per 100 000 population) were calculated overall as well as by state/territory and medication type/class. Percentage change (Δ) in dispensing rates from 2014 to 2023 was determined. Where valid, Mann-Kendall trend tests were performed.</p><p><strong>Results: </strong>Australia-wide from 2014 to 2023, dispensing counts per 100 000 population for any OAMs increased nonlinearly from 3 475 to 3 930 (+Δ13%), hormonal OAMs decreased nonlinearly from 2 659 to 2 225 (-Δ16%), and non-hormonal OAMs exhibited a significant (p < 0.05) near-linear upward trend from 816 to 1 705 (+Δ109%). This coincided with a significant upward trend in the number of unique non-hormonal OAMs dispensed Australia-wide (+Δ187%). Percentage changes in non-hormonal OAM dispensing rates were greatest for protein kinase inhibitor (PKI) dispensing Australia-wide (+Δ232%), with a significant, near-linear upward trend from 286 to 950, and non-hormonal OAM dispensing in South Australia (+Δ141%), with a significant, near-linear upward trend from 820 to 1972.</p><p><strong>Conclusions: </strong>Australia's non-hormonal OAM dispensing increased over 2014-2023, mostly for PKIs. This likely reflects rising availability of and prescriber/patient demand for these medications, suggesting scope to pilot and expand OAM adherence and safety initiatives.</p>\",\"PeriodicalId\":19782,\"journal\":{\"name\":\"Pharmacoepidemiology and Drug Safety\",\"volume\":\"34 4\",\"pages\":\"e70126\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11934842/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacoepidemiology and Drug Safety\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/pds.70126\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacoepidemiology and Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pds.70126","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Trends in the Dispensing of Oral Anti-Cancer Medications Across Australia Over 10 Years.
Purpose: Oral anti-cancer medications (OAMs) are easily administered yet high-risk treatments. Few studies have investigated national and subnational trends in OAM dispensing. We aimed to examine 10-year trends in Australia's OAM dispensing at the national level as well as by state/territory and medication type/class.
Methods: Aggregate data on Australia's OAM dispensing and population for 2014-2023 were sourced from Services Australia and the Australian Bureau of Statistics, respectively. Annual OAM dispensing rates (counts per 100 000 population) were calculated overall as well as by state/territory and medication type/class. Percentage change (Δ) in dispensing rates from 2014 to 2023 was determined. Where valid, Mann-Kendall trend tests were performed.
Results: Australia-wide from 2014 to 2023, dispensing counts per 100 000 population for any OAMs increased nonlinearly from 3 475 to 3 930 (+Δ13%), hormonal OAMs decreased nonlinearly from 2 659 to 2 225 (-Δ16%), and non-hormonal OAMs exhibited a significant (p < 0.05) near-linear upward trend from 816 to 1 705 (+Δ109%). This coincided with a significant upward trend in the number of unique non-hormonal OAMs dispensed Australia-wide (+Δ187%). Percentage changes in non-hormonal OAM dispensing rates were greatest for protein kinase inhibitor (PKI) dispensing Australia-wide (+Δ232%), with a significant, near-linear upward trend from 286 to 950, and non-hormonal OAM dispensing in South Australia (+Δ141%), with a significant, near-linear upward trend from 820 to 1972.
Conclusions: Australia's non-hormonal OAM dispensing increased over 2014-2023, mostly for PKIs. This likely reflects rising availability of and prescriber/patient demand for these medications, suggesting scope to pilot and expand OAM adherence and safety initiatives.
期刊介绍：
The aim of Pharmacoepidemiology and Drug Safety is to provide an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology. The Journal publishes peer-reviewed reports of original research, invited reviews and a variety of guest editorials and commentaries embracing scientific, medical, statistical, legal and economic aspects of pharmacoepidemiology and post-marketing surveillance of drug safety. Appropriate material in these categories may also be considered for publication as a Brief Report.
Particular areas of interest include:
design, analysis, results, and interpretation of studies looking at the benefit or safety of specific pharmaceuticals, biologics, or medical devices, including studies in pharmacovigilance, postmarketing surveillance, pharmacoeconomics, patient safety, molecular pharmacoepidemiology, or any other study within the broad field of pharmacoepidemiology;
comparative effectiveness research relating to pharmaceuticals, biologics, and medical devices. Comparative effectiveness research is the generation and synthesis of evidence that compares the benefits and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition, as these methods are truly used in the real world;
methodologic contributions of relevance to pharmacoepidemiology, whether original contributions, reviews of existing methods, or tutorials for how to apply the methods of pharmacoepidemiology;
assessments of harm versus benefit in drug therapy;
patterns of drug utilization;
relationships between pharmacoepidemiology and the formulation and interpretation of regulatory guidelines;
evaluations of risk management plans and programmes relating to pharmaceuticals, biologics and medical devices.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
